These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25921689)

  • 1. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
    Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
    AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
    Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
    Kearney BP; Mathias A; Mittan A; Sayre J; Ebrahimi R; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):278-83. PubMed ID: 17079992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
    Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
    Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
    J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
    Mizushima D; Nguyen DTH; Nguyen DT; Matsumoto S; Tanuma J; Gatanaga H; Trung NV; van Kinh N; Oka S
    J Infect Chemother; 2018 Jul; 24(7):549-554. PubMed ID: 29602711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
    Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
    AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.